Skip to main content

Normal Eyes

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
BI Anterior Segment ModeN/A1 trial
Active Trials
NCT03578302Completed39Est. Dec 2018
Optos
OptosUK - Dunfermline
1 program
P200TEN/A1 trial
Active Trials
NCT05844852Unknown800Est. May 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
OptosP200TE
Heidelberg PharmaBI Anterior Segment Mode

Clinical Trials (2)

Total enrollment: 839 patients across 2 trials

P200TE US Reference Database Study

Start: Mar 2023Est. completion: May 2024800 patients
N/AUnknown
NCT03578302Heidelberg PharmaBI Anterior Segment Mode

The Heidelberg Engineering BI US Evaluation Study

Start: May 2018Est. completion: Dec 201839 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.